Silverback Therapeutics, Inc. – NASDAQ:SBTX
Silverback Therapeutics stock price today
Silverback Therapeutics stock price monthly change
Silverback Therapeutics stock price quarterly change
Silverback Therapeutics stock price yearly change
Silverback Therapeutics key metrics
Market Cap | 550.43M |
Enterprise value | 5.12M |
P/E | -2.43 |
EV/Sales | N/A |
EV/EBITDA | -0.06 |
Price/Sales | N/A |
Price/Book | 0.77 |
PEG ratio | 0.01 |
EPS | 0.71 |
Revenue | N/A |
EBITDA | -32.09M |
Income | -14.69M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSilverback Therapeutics stock price history
Silverback Therapeutics stock forecast
Silverback Therapeutics financial statements
| Dec 2022 | 0 | 28.75M | |
|---|---|---|---|
| Mar 2023 | 0 | -11.20M | |
| Jun 2023 | 0 | -17.37M | |
| Sep 2023 | 0 | -14.86M |
| 2022-08-11 | -0.48 | -0.55 |
|---|---|---|
| 2022-11-02 | -0.35 | -0.5 |
| Dec 2022 | 281435000 | 8.54M | 3.04% |
|---|---|---|---|
| Mar 2023 | 271192000 | 10.03M | 3.7% |
| Jun 2023 | 258752000 | 10.2M | 3.94% |
| Sep 2023 | 248556000 | 11.27M | 4.53% |
| Dec 2022 | 11.39M | 485K | 189.39M |
|---|---|---|---|
| Mar 2023 | -12.42M | -111.54M | 1.31M |
| Jun 2023 | 356K | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
Silverback Therapeutics alternative data
| Aug 2023 | 90 |
|---|---|
| Sep 2023 | 90 |
| Oct 2023 | 90 |
| Nov 2023 | 90 |
| Dec 2023 | 90 |
| Jan 2024 | 90 |
| Feb 2024 | 90 |
| Mar 2024 | 90 |
| Apr 2024 | 90 |
| May 2024 | 90 |
| Jun 2024 | 90 |
| Jul 2024 | 90 |
Silverback Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Nov 2022 | 8250 | 43896 |
| May 2023 | 0 | 100000 |
| Jun 2023 | 0 | 100000 |
| Jul 2023 | 0 | 100000 |
| Aug 2023 | 4750000 | 100000 |
| Sep 2023 | 2786258 | 100000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | FITZPATRICK ALEXANDER A officer: Chief Legal Officer | Common Stock | 46,258 | $3.78 | $174,994 | ||
Purchase | FITZPATRICK ALEXANDER A officer: Chief Legal Officer | Common Stock | 40,000 | $3.62 | $144,960 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director | Common Stock | 191,309 | $3.83 | $732,713 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director | Common Stock | 2,508,691 | $2.97 | $7,450,812 | ||
Option | SHAWVER LAURA director | Stock Option (Right to Buy) | 2,997 | $1.27 | $3,806 | ||
Option | SHAWVER LAURA director | Stock Option (Right to Buy) | 97,003 | $1.27 | $123,194 | ||
Option | SHAWVER LAURA director | Common Stock | 97,003 | $1.27 | $123,194 | ||
Option | SHAWVER LAURA director | Common Stock | 2,997 | $1.27 | $3,806 | ||
Sale | SHAWVER LAURA director | Common Stock | 100,000 | $7.71 | $770,500 | ||
Purchase | RA CAPITAL MANAGEMENT, L.P. director | Common Stock | 3,750,000 | $6.2 | $23,250,000 |
| Patent |
|---|
Application Filling date: 18 Jun 2020 Issue date: 11 Aug 2022 |
Application Filling date: 5 Mar 2020 Issue date: 2 Jun 2022 |
Application Filling date: 4 Oct 2021 Issue date: 7 Apr 2022 |
Application Filling date: 12 Sep 2019 Issue date: 17 Feb 2022 |
Application Filling date: 19 Feb 2021 Issue date: 9 Sep 2021 |
Application Filling date: 24 Jun 2020 Issue date: 27 May 2021 |
Application Filling date: 2 Apr 2019 Issue date: 27 May 2021 |
Application Filling date: 16 Jul 2020 Issue date: 13 May 2021 |
Application Filling date: 9 Oct 2020 Issue date: 6 May 2021 |
Application Filling date: 23 Apr 2020 Issue date: 22 Apr 2021 |
-
What's the price of Silverback Therapeutics stock today?
One share of Silverback Therapeutics stock can currently be purchased for approximately $5.87.
-
When is Silverback Therapeutics's next earnings date?
Unfortunately, Silverback Therapeutics's (SBTX) next earnings date is currently unknown.
-
Does Silverback Therapeutics pay dividends?
No, Silverback Therapeutics does not pay dividends.
-
How much money does Silverback Therapeutics make?
Silverback Therapeutics has a market capitalization of 550.43M. Silverback Therapeutics made a loss 33.85M US dollars in net income (profit) last year or -$0.5 on an earnings per share basis.
-
What is Silverback Therapeutics's stock symbol?
Silverback Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SBTX".
-
What is Silverback Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Silverback Therapeutics?
Shares of Silverback Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Silverback Therapeutics's key executives?
Silverback Therapeutics's management team includes the following people:
- Dr. Laura K. Shawver Chief Executive Officer & Director(age: 67, pay: $786,650)
- Dr. Valerie Odegard Ph.D. Pres & Chief Scientific Officer(age: 48, pay: $552,380)
- Mr. Jonathan Piazza Chief Financial Officer(age: 49, pay: $299,890)
- Dr. Peter A. Thompson M.D. Co-Founder & Chairman of Directors(age: 65, pay: $5,120)
-
Is Silverback Therapeutics founder-led company?
Yes, Silverback Therapeutics is a company led by its founder Dr. Peter A. Thompson M.D..
-
How many employees does Silverback Therapeutics have?
As Jul 2024, Silverback Therapeutics employs 90 workers.
-
When Silverback Therapeutics went public?
Silverback Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 3 Dec 2020.
-
What is Silverback Therapeutics's official website?
The official website for Silverback Therapeutics is silverbacktx.com.
-
Where are Silverback Therapeutics's headquarters?
Silverback Therapeutics is headquartered at 500 Fairview Avenue North, Seattle, WA.
-
How can i contact Silverback Therapeutics?
Silverback Therapeutics's mailing address is 500 Fairview Avenue North, Seattle, WA and company can be reached via phone at +20 64 562900.
Silverback Therapeutics company profile:
Silverback Therapeutics, Inc.
silverbacktx.comNASDAQ
90
Biotechnology
Healthcare
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Seattle, WA 98109
CIK: 0001671858
ISIN: US82835W1080
CUSIP: 82835W108
